Tevogen Bio Holdings Inc. (NASDAQ:TVGN – Get Free Report) shares gapped down prior to trading on Friday . The stock had previously closed at $2.56, but opened at $2.49. Tevogen Bio shares last traded at $2.95, with a volume of 13,727,006 shares trading hands.
Tevogen Bio Price Performance
The stock’s 50 day moving average is $0.72 and its two-hundred day moving average is $0.86.
Insider Buying and Selling
In other Tevogen Bio news, insider Neal Flomenberg sold 1,078,600 shares of the business’s stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $1.62, for a total value of $1,747,332.00. Following the sale, the insider now owns 4,254,302 shares in the company, valued at approximately $6,891,969.24. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 56.60% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Tevogen Bio Company Profile
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Read More
- Five stocks we like better than Tevogen Bio
- Investing In Preferred Stock vs. Common Stock
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Investing In Automotive Stocks
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Differences Between Momentum Investing and Long Term Investing
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Tevogen Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tevogen Bio and related companies with MarketBeat.com's FREE daily email newsletter.